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ABSTRACT: The plasma levels of vitamin C, vitamin E and uric acid were determined in leprosy subjects from in 
Ossiomo leprosorium settlement in Edo state, Nigeria. In this study, antioxidant status were determined in a total of 
86 subjects that comprised of 31 leprosy patients on multidrug therapy (MBT), 40 leprosy patients relieved from 
therapy (RFT) in Ossiomo leprosorium settlement and 15 normal individuals who served as control subjects. Of the 
MDT group, 10 subjects were paucibacillary (PB) leprosy patients while 21 were multibacillary (MB) patients.  There 
were significant decreases (P<0.05) in the plasma vitamin C and vitamin E levels relative to the controls. However 
the uric acid level was higher in the leprosy patients (P<0.05) compared with the control subjects. The uric acid 
levels determined in the RFT patients (10.74±0.99) obtained was significantly higher than those of MDT patients 
(2.90±0.29) and controls (6.69±0.32). The observed decrease in the vitamin C and vitamin E levels in the leprosy 
patients could be as a result of the free radicals produced during metabolism of the chemotherapeutic agents 
administered to the patients and the chronic pathological effects of Mycobacterium leprae on the population 
studied. 
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Leprosy, also known as Hansenʼs disease is caused by 
Mycobacterium leprae. It is characterized by damage to the 
skin, peripheral nerves and the lining of the upper respiratory 
tract. As a result of the nerve damage, there may be 
paralysis, deformity and ulceration (Macleod, 1984). World 
Health Organization (WHO 1998) listed Nigeria along with 
other countries such as Bangladesh, Brazil, India, Indonesia 
and Myanmar where the disease is still endemic (Jacobson 
and Krahenbuhl 1999).  
For treatment purposes, leprosy patients are classified into 
three groups: paucibacillary single-lesion leprosy, 
paucibacillary leprosy and multibacillary leprosy. Skin smears 
were originally used to distinguish between paucibacillary 
and multibacillary leprosy. However, because services for 
processing skin smears are not always available, and also 
because their reliability is often doubtful, in practice most 
leprosy programmes classify and choose the appropriate 
regimen for a particular patient using clinical criteria, which 
uses the number of skin lesions and nerves involved to 
classify leprosy patients into paucibacillary single-lesion 
leprosy (one skin lesion), paucibacillary (PB) leprosy (2-5 
skin lesions) and multibacillary (MB) leprosy (more than five 
skin lesions). When skin smears are available and are 
dependable, any patient with a positive skin smear, 
irrespective of the clinical picture, must be classified as 
multibacillary leprosy and must be treated with the multidrug 
therapy regimen for multibacillary leprosy. 
Several drugs are used in combination in the treatment of 
leprosy as part of a multidrug therapy regimen (WHO, 1998). 
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Dapsone, which is bacteriostatic or weakly bactericidal 
against M. leprae, was the mainstay treatment for leprosy for 
many years until widespread resistant strains appeared. 
Combination therapy has become essential to slow or 
prevent the development of resistance. Rifampicin is now 
combined with dapsone to treat paucibacillary leprosy, while 
rifampicin and clofazimine are now combined with dapsone 
to treat multibacillary leprosy (WHO, 1998). 
Krinsky (1992) describes antioxidants as compounds that 
protect biological systems against the potentially harmful 
effects of processes or reactions that can cause excessive 
oxidation (such as produced by this disease and drugs for its 
treatment). The destructive potentials of M. leprae (Macleod, 
1984) and metabolic effects of the antileprosy drugs are 
capable of producing oxidative damage to macromolecules, 
such as lipids, protein, carbohydrates and nucleic acid, 
ultimately leading to cells necrosis in patients (Halliwell and 
Gutteridge, 1989). Humans have antioxidant defense 
mechanisms against reactive oxygen species; among the 
oxidants are vitamins A, C and E, enzymes such as 
superoxide dismutase and catalase. (Waring, 2002). 
One of the roles of Vitamins C, A and E is that of scavenging 
for free radicals in the aqueous phase of cells and the 
circulatory system to mop up generated reactive oxygen 
species (Beyer, 1994; Chamorro et al, 2002; Waring, 2002; 
Squadrito et al, 2000). One of the multidrug therapy (MDT) 
drugs for leprosy dapsone is strongly oxidative in a way that 
damages the membranes red blood cells and results in 
haemolysis. It was shown that combined therapy of Vitamin 
C and Vitamin E confers partial protective effects against 
dapsone-induced haemolysis in patients with dermititis and 
herpetiformis (Lardo et al. 1997). In a similar manner, 
Vitamins A and E were used to relief mouth sores arising as 
common sides effects of chemotherapy (Wadleigh et al 
1992). 
For many years, uric acid has been used in clinical practice 
as a marker of several metabolic disturbances, although, until 
recently, its oxidants properties had not been considered 
(Chamorro et al, 2002). It has been specifically postulated 
that uric acid, the naturally occurring product of urine 
metabolism, may provide endogenous natural protection 
against the oxidative injury occurring as a result of 
peroxynitrtate exposure by acting as an endogenous free 
radical scavenger or oxidant (Waring 2002). 
Leprosy imposes oxidative stress on its victims, which is 
further compounded by chemotherapy. In the more 
developed nations of America and Europe, the contributions 
of chemotherapy and antioxidants such as vitamin C, and 
vitamin E and in the treatment of leprosy have been well 
documented and dietary modification is fast becoming an 
acceptable part of the management protocol for this disorder 
in developed parts of the world (Trimbake et al., 2013). 
However, information on the oxidative status of Nigerian 
leprosy patients is scare. The role of antioxidants (especially 
uric acid) in leprosy has received limited attention in this part 
of the world. In this study, the effects of leprosy on non-
enzymatic antioxidants (vitamin C, E and uric acid) were 
studied in Ossiomo leprosorium settlement in Edo state. 
 
MATERIALS AND METHODS 
Subjects 
A total of 86 subjects comprising of seventy-one leprosy 
patients from Ossiomo leprosarium specialist hospital, Ogan, 
Edo state, Nigeria were involved in this study. A different set 
of fifteen non-leprous subjects, within the same age and sex 
and in similar socio-economic and environmental status 
served as control. Of the seventy-one leprosy patients, thirty-
one of them were on multidrug therapy (MDT) while forty 
were leprosy patients relieved from therapy (RFT). The MDT 
group were further subdivided into (a) Ten Paucibacillary 
(PB) leprosy patients and (b) twenty-one multibacillary (MB) 
leprosy patients. Six month regimen for Paucibacillary (PB) 
leprosy adult of 50-70 kg, was dapsone 100 mg and 
rifampicin 600 mg daily while the 12 month regimen for 
Multibacillary (MB) Leprosy adult of 50-70 kg was dapsone 
100 mg and rifampicin 600 mg daily and clofazimine 50 mg 
once a month. Since these drugs are not recommended for 
pregnant women and children, individuals from these two 
groups were not included in the study. Informed consent was 
obtained from all subjects prior to the commencement of the 
experiment and sample collection. The subsequent 
biochemical analyses were carried out within two hours of 
sample collection. 
Biochemical Assays 
All parameters (vitamin C, vitamin E, and Uric acid) were 
determined using standard procedures (Wadleigh; et al 1992; 
Sauberlich, et al 1974; Roe and Kuether, 1943). The 
parameters were determined using test kits from Randox 
Laboratories, U.K. The protocols used were based on the kit 
manufacturerʼs instructions. 
Statistical Analysis 
The group mean ± SEM was calculated for each analyte and 
significant differences between means evaluated using the 
student t-test, with P<0.05 considered as statistically 
significant. 
 
RESULTS AND DISCUSSION 
In this study, the non-enzymatic antioxidants (vitamin C, 
vitamin E and Uric acid) status of eighty-six subjects was 
investigated. There was a general decrease in the levels of 
vitamins C and E in leprosy patients (Figure 1).  




However, the level of uric acid in leprosy patients was not 
significantly different from that of the control subjects 
(P>0.05). In order to gain a better understanding of the 
results pattern, we compared the antioxidants level in 
paucibacillary and multibacillary leprosy patients with the 
control subjects. Figure 2 shows that vitamin C, E and Uric 
acid were significantly reduced (P<0.05) in both 
paucibacillary and multibacillary leprosy patients when 
compared with the control subjects. The negative influence of 
leprosy disease on the plasma levels of the antioxidants 
(vitamins C, E) studied as shown in Figures 1 and 2 above 
agrees with the work of (Vijayaraghavan and 
Panneerselvam, 2005) that antioxidants may provide first line 
defense against reactive oxygen species (ROS) generated in 
disease conditions. Hence, depletion of the antioxidants in 
the patients may reflect disease-combating mechanisms. 
 
 
On the other hand, a pre-existing low antioxidant level could 
be a pre-disposing factor toward susceptibility to leprosy. 
Leprosy continues to afflict a large number of people globally 
as shown from several studies (Gandhi and Singh, 2004). 
The antioxidants (Vitamins C, E and Uric acid) status of the 
patients investigated in this study revealed a statistically 
significant decrease (p<0.05) when compared with the 
control subjects. This suggests that leprosy patients, 
irrespective of their drug therapy status or disease type, have 
significantly reduced levels of antioxidants. In an earlier 
study, Florence (1995) concluded that all leprosy patients 
had a mild to moderate lowering of antioxidants especially 
when nutrition and immunological status of the patients are 
compromised. This low antioxidant level appears to be 
associated with poverty, since all leprosy patients belonged 
to the low economic status. 
Figure 1: Levels of serum antioxidants (vitamin C, E and Uric Acid) in control subjects and all leprosy subjects 
irrespective of drug status. Each bar represents the mean ± SEM of the number of subjects as indicated. 
 
Figure 2: Comparison of the levels of serum antioxidants (vitamin C, E and Uric Acid) between paucibacillary (PB) 
and multibacillary (MB) leprosy patients and controls. Each bar represents the mean ± SEM of the number of 
subjects as indicated. 
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Though the antioxidants levels were generally low among the 
leprosy patients, a closer look at the two disease types 
revealed that the antioxidants vitamin C and Vitamin E had 
higher concentrations in PB leprosy patients than those with 
MB (p<0.05). Hooper (2000) had shown that PB leprosy 
patients have higher immunity compared with the MB group.  
This could be as a result of the low bacterial load of the 
causative organism M. Leprae. PB patients are better able to 
eliminate bacteria through cell–mediated immunity (Hooper et 
al; 2000; Lopez, 1994; Kelly et al; 1990). 
Figure 3 shows that the levels of vitamin C and E in both 
patients on MDT and those in the RFT groups were markedly 
reduced (P<0.05) compared with the controls. This indicates 
that current or previous exposure to MDT generally had an 
effect on the antioxidant status of leprosy patients. Clear 
evidence have been provided that dapsone, one of the MDT 
drugs used in treating leprosy is strongly oxidative, and 
induces hemolysis (Kelly et al; 1990; Lardo et al, 1997). The 
increase in free radicals generated in the course of therapy 
could cause a reduction in the antioxidants. In this work, the 
level of uric acid (Figure 3) was found to be lower in patients 
on MDT compared with those RFT and normal controls 
(Lardo et al, 1997). Kong and Lillehi (1998) suggested from 
their work that over production of reactive oxygen species 
(ROS) following therapy exhausts the production of adaptive 
oxidants defenses. 
Of particular interest in this study, is the observed difference 
in the uric acid levels obtained for the two leprosy groups 
(MDT and RFT). Leprosy patients on MDT had significantly 
decreased level of uric acid (p<0.05) compared with controls 
and those in the RFT group. The observed decrease in the 
uric acid level in all leprosy patients on MDT could be due to 
the presence of ROS resulting from the therapeutic drugs, 
which the uric acid tries to mop-up, thereby resulting in a 
decrease in antioxidant potential. 
Uric acid is a strong peroxynitrite (ONOO-) scavenger 
demonstrated by the capacity to bind peroxynitrite but not 
nitric oxide (NO). Patients with multiple sclerosis have been 
shown to have significantly lower levels of Uric acid than 
controls (Chamorro et al., 2002) probably this is what is 
happening in this of leprosy. This study amongst other things 
suggests that Nigerian leprosy patients irrespective of 
whether they are on multi drug therapy (MDT) or relieved 
from therapy (RFT) have lowered plasma non-enzymatic 
antioxidants (vitamin C, E and Uric acid) except for those 
RFT whose Uric acid has a high level than those on MDT and 
control subjects. The free radical producing ability from drugs 
used in the MDT and the influence of M. leprae seemed to 
have a reducing effect on the antioxidants capacity of the 
patients. 
Antioxidants are best supplied by balanced diet, but 
unfortunately leprosy patients are of the low socioeconomic 
status. Therefore, it is reasonable to say that there is need 
for intervention with antioxidants supplements. 
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